Hofseth BioCare Q2 operating revenue slips on lower raw material volumes

Hofseth Biocare ASA

21/08/2026 07:31

Overview
Norway consumer and pet health firm's Q2 operating revenue declined yr/yr
Q2 EBITDA loss narrowed compared to same period last year
Company completed private placement raising NOK 144.5 mln to strengthen liquidity

Outlook
Company did not provide specific financial guidance for the current or upcoming periods

Result Drivers
HIGHER SELLING PRICES - Co said average selling prices for ProGo and OmeGo more than doubled yr/yr, supported by tight global marine protein and fish oil markets
LOWER RAW MATERIAL USE - Co achieved Q2 revenue with about 44% less raw material processed than in Q2 2025
B2B CONSUMER HEALTH GROWTH - B2B Consumer Health revenue grew 72% quarter-on-quarter, helped by a global exclusive agreement and new product launch

Company press release: ID:nGNE9YHjcG

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
NOK 65.70 mln
 
Q2 EBITDA
 
-NOK 2.70 mln
 

Reuters Recommended Reads
Aug 19 - Austevoll Seafood Q2 revenue misses estimates on lower salmon volumes
Aug 19 - Norway's Lerøy Seafood Q2 EBIT falls on lower harvest volumes
Aug 20 - Norway's Orkla Q2 adjusted EPS rises 2.6%, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)